For decades research has relied on animal models to acquire understanding of pathological processes and to identify targets for drug development. It cannot be denied that ground-breaking and Nobel prize winning results were obtained, but this era of glory seems to be over as the low hanging fruits have been taken. Indeed, looking back at the last two decades of research into the pathologic processes leading to cancer, neurodegeneration and arthrosclerosis, failure rates with respect to translat…
For decades research has relied on animal models to acquire understanding of pathological processes and to identify targets for drug development. It cannot be denied that ground-breaking and Nobel prize winning results were obtained, but this era of glory seems to be over as the low hanging fruits have been taken. Indeed, looking back at the last two decades of research into the pathologic processes leading to cancer, neurodegeneration and arthrosclerosis, failure rates with respect to translation into human benefit, were 80%, 99% and 100%, despite huge investments. During the BioMed21 workshops federal agencies, funding agencies, regulators, and academics explored existing approaches and potential improvements in development, access, storage, and evaluation of human-relevant information with the goal of enhancing human disease research. One recommendation is the adaptation of the Adverse Outcome Pathway (AOP) concept for mapping perturbations of normal human physiology during disease development. The AOP concept, currently applied in toxicology, has since been being applied to capture complex biological knowledge about non-communicable and communicable human diseases. It is believed that this approach can enable new target discovery as exemplified by the AOP for developmental vascular toxicity (AOP43). In this book it is described how the AOP concept can be used to build AOPs and AOP networks, as well as gene interaction networks, providing new insight into the early processes driving memory loss and the impact of environmental factors on these processes translates into accelerated deterioration of these aging-related processes towards Alzheimer's related dementia.
For decades research has relied on animal models to acquire understanding of pathological processes and to identify targets for drug development. It cannot be denied that ground-breaking and Nobel prize winning results were obtained, but this era of glory seems to be over as the low hanging fruits have been taken. Indeed, looking back at the last two decades of research into the pathologic processes leading to cancer, neurodegeneration and arthrosclerosis, failure rates with respect to translation into human benefit, were 80%, 99% and 100%, despite huge investments. During the BioMed21 workshops federal agencies, funding agencies, regulators, and academics explored existing approaches and potential improvements in development, access, storage, and evaluation of human-relevant information with the goal of enhancing human disease research. One recommendation is the adaptation of the Adverse Outcome Pathway (AOP) concept for mapping perturbations of normal human physiology during disease development. The AOP concept, currently applied in toxicology, has since been being applied to capture complex biological knowledge about non-communicable and communicable human diseases. It is believed that this approach can enable new target discovery as exemplified by the AOP for developmental vascular toxicity (AOP43). In this book it is described how the AOP concept can be used to build AOPs and AOP networks, as well as gene interaction networks, providing new insight into the early processes driving memory loss and the impact of environmental factors on these processes translates into accelerated deterioration of these aging-related processes towards Alzheimer's related dementia.
Atsiliepimai
Atsiliepimų nėra
0 pirkėjai įvertino šią prekę.
5
0%
4
0%
3
0%
2
0%
1
0%
Kainos garantija
Ženkliuku „Kainos garantija” pažymėtoms prekėms Knygos.lt garantuoja geriausią kainą. Jei identiška prekė kitoje internetinėje parduotuvėje kainuoja mažiau - kompensuojame kainų skirtumą. Kainos lyginamos su knygos.lt nurodytų parduotuvių sąrašu prekių kainomis. Knygos.lt įsipareigoja kompensuoti kainų skirtumą pirkėjui, kuris kreipėsi „Kainos garantijos” taisyklėse nurodytomis sąlygomis. Sužinoti daugiau
Elektroninė knyga
22,39 €
DĖMESIO!
Ši knyga pateikiama ACSM formatu. Jis nėra tinkamas įprastoms skaityklėms, kurios palaiko EPUB ar MOBI formato el. knygas.
Svarbu! Nėra galimybės siųstis el. knygų jungiantis iš Jungtinės Karalystės.
Tai knyga, kurią parduoda privatus žmogus. Kai apmokėsite užsakymą, jį per 7 d. išsiųs knygos pardavėjas . Jei to pardavėjas nepadarys laiku, pinigai jums bus grąžinti automatiškai.
Šios knygos būklė nėra įvertinta knygos.lt ekspertų, todėl visa atsakomybė už nurodytą knygos kokybę priklauso pardavėjui.
Perskaityta knyga:
Nenauja knyga, kuri parduodama tiesiai iš knygos.lt sandėlio. Knygos kokybė įvertinta knygos.lt ekspertų.
Tai knyga, kurią parduoda privatus žmogus. Kai apmokėsite užsakymą, jį per 7 d. išsiųs knygos pardavėjas . Jei to pardavėjas nepadarys laiku, pinigai jums bus grąžinti automatiškai.
Šios knygos būklė nėra įvertinta knygos.lt ekspertų, todėl visa atsakomybė už nurodytą knygos kokybę priklauso pardavėjui.
Atsiliepimai